Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Medivation Inc    MDVN   US58501N1019


News SummaryMost relevantAll newsSector news 

Medivation Inc : Medivation Announces Participation at Upcoming Investor Conferences

10/30/2013 | 04:34pm US/Eastern

SAN FRANCISCO, CA -- (Marketwired) -- 10/28/13 -- Medivation, Inc. (NASDAQ: MDVN) today announced that it will host a live teleconference with management to discuss third quarter 2013 financial results and provide a general business update on November 12, 2013 at 4:30 p.m. Eastern Time. A press release for the third quarter of 2013 will be released after markets close on November 12, 2013.

Interested parties may listen to the live teleconference by calling 877-303-2523 from the U.S. or +1-253-237-1755 internationally. Individuals may access the live audio webcast by visiting:

About Medivation
Medivation, Inc. is a biopharmaceutical company focused on the rapid development of novel therapies to treat serious diseases for which there are limited treatment options. Medivation aims to transform the treatment of these diseases and offer hope to critically ill patients and their families. For more information, please visit us at

Patrick Machado
Chief Business & Financial Officer
(415) 829-4101

Anne Bowdidge
Sr. Director, Investor Relations
(650) 218-6900

Source: Medivation

News Provided by Acquire Media

distributed by
React to this article
Latest news on MEDIVATION INC
09:01a MEDIVATION : Market Updates on Biotech Stocks -- Lexicon Pharma, Idera Pharma, S..
04/23 MEDIVATION : Announces First Quarter 2015 Financial Results Teleconference on Ma..
04/22 Tokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Mediv..
04/16 Tokai Pharmaceuticals Names Cheryl Cohen to Its Board
04/14 Tokai Pharmaceuticals Announces the Appointment of Cheryl Cohen, Former Mediv..
04/04 MEDIVATION : and Astellas Release New Enzalutamide Data
04/03 MEDIVATION : Astellas -enzalutamide demonstrates statistically significant impro..
04/02 MEDIVATION : Enzalutamide Demonstrates Statistically Significant Improvement In ..
04/02 MEDIVATION : Enzalutamide Demonstrates Statistically Significant Improvement in ..
04/01 ASTELLAS PHARMA : and Medivation Announce New Enzalutamide Data Presented During..
Duration : Period :
Medivation Inc Technical Analysis Chart | MDVN | US58501N1019 | 4-Traders
Income Statement Evolution
More Financials
Dynamic quotes